NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (" 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

The field of gynecological oncology has been significantly transformed by the advancements in molecular biology and precision medicine. These innovations ...

Candel Therapeutics, Inc. (NASDAQ:CADL) has secured FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its ...

This nationwide academic grant invites eligible healthcare students to present visionary ideas about the future of aging, ...

The process of necrosis, a form of cell death, may represent one of the most promising ways to change the course of human aging, disease and even space travel, according to a new study by researchers ...

Housing, workforce development, education and child care were all topics during the Regen Valley Tech Hub Community Update, ...

The FDA's RMAT designation is intended to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening diseases where ...

Shares of Candel Therapeutics, Inc. (CADL) traded 8% higher on Wednesday morning after the U.S. Food and Drug Administration ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Since the COVID-19 pandemic, global interest in antiviral therapies has increased significantly. Recently, with the growing ...

Consideration of how the extracellular matrix directs cell behavior will be crucial to the success of regenerative therapies. Context-specific mechanical deformation of particular substrates ...